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Summary Helix pomatia agglutinin (HPA)- and Concanavalin A (Con A)-binding carbohydrate expression
were studied on 32 tumour samples from primary adenocarcinoma of the breast and 12 samples from lymph
node metastases. Live cells were spilled from each of the fresh samples and the extent of fluorescent-labelled
HPA and Con A-binding was assessed by flow cytometry. The extent of brightness was expressed in a defined
quantitative fashion and the percentage of positive cells was accurately determined from a sample of 10,000
cells per tumour. Correlation of binding with clinicopathological features showed that HPA but not Con A
related to lymph node involvement (P=0.001) in tumours of higher grade (II and III). Spilled tumour cells
(non-lymphocytes) were selected from the lymph nodes and the presence of HPA binding cells in the involved
lymph nodes was found to relate to positive HPA binding in autologous primary tumours (P=0.002).
Dual-label analysis of HPA and Con A binding showed characteristic features for each tumour. The study
demonstrates the use of flow cytometry as a simple and effective technique in detecting differences in lectin
binding in live spilled cells from fresh breast cancer tissues. This method may prove to be particularly useful if
performed preoperatively on cells in fine-needle aspirates.
In recent years there has been an increase in studies aimed at
detecting differences between primary tumours and their
metastases and between clones of cells with high or low
metastatic potential. Cell surface carbohydrate expression
appears to be related to metastatic potential and differences
in cell surface carbohydrates have been demonstrated with
animal tumours selected for high and low metastatic sublines
(Altevogt et al., 1983; Irimura & Nicolson, 1984; Steck &
Nicolson, 1983). The importance of carbohydrate expression
in malignant cells has also been highlighted by work with
monoclonal antibodies. Monoclonal antibodies reactive with
breast carcinoma have been shown to recognize determinants
which are on high molecular weight glycoproteins (Tjandra &
McKenzie, 1988), though the precise structure of these deter-
minants is still unknown. Currently, differences in cell surface
carbohydrate expression are detected using lectins and in a
number of studies with human breast cancer tissues such
differences have been shown to be of prognostic significance.
In a 20-year retrospective study, Leathem & Brooks (1987)
found Helix pomatia agglutinin (HPA) binding to be
associated with metastasis to local lymph node in
premenopausal women. Another finding relating HPA bin-
ding to lymph node stage, time to locoregional recurrence
and to survival, and also Ulex europeus (UEA I) binding to
disease-free interval and survival was reported by Fenlon et
al. (1987). Concanavalin A (Con A) binding has also been
implicated in disease progression in primary cultures of
breast cancer cells (Furmanski et al., 1981). Con A reactivity
was also reported to be negative in normal breast tissue,
whereas positive Con A binding was related to stage and
disease-free survival (Dansey et al., 1988). However, in a
multivariate analysis the differences in Con A binding were
explained by the association with the stage of the disease
(Dansey et al., 1988). In the same report, peanut (Arachis
hypogea) lectin (PNA) and wheat germ agglutinin (WGA)
binding was found not to correlate with the clinical outcome.
A significant correlation has also been reported between
decreased WGA reactivity and the presence of lymph node
metastasis (Walker, 1984). However, another study reported
no differences in WGA binding to breast carcinomas with, or
without, axillary lymph node involvement (Khan & Baumal,
1985). With the exception of the study of Furmanski et al.
(1981), which used haemadsorption assay, these studies on
lectin binding involved histochemical analysis which required
the use of fluorescently-labelled lectins to stain formalin-
fixed, paraffin-embedded tissue sections.
Two fluorescently-labelled lectins were used in this study,
Helix pomatia agglutinin (HPA) with binding specificity to
N-acetyl galactosamine and Concanavalin A (Con A) with
binding specificity to mannose and glucose residues. Using
flow cytometry to detect the extent of lectin binding, the
present investigation was carried out to assess the value of
HPA and Con A binding to live tumour cells from fresh
human breast cancers. Flow cytometry offers several advan-
tages over the conventional histochemical analysis, especially
as it does not require pretreatment with any fixative reagent
and live cells can easily be selected for the study. Moreover, a
large number of cells (typically 10,000) can be analysed in a
non-subjective manner in a short period of time and the
extent of brightness can be accurately quantified. Dual label
analysis with two lectins of differing specificity (HPA and
Con A) can also be carried out to explore the heterogeneity
of tumour cells in relation to carbohydrate expression.
Differences in lectin binding can be correlated to various
clinicopathological features.
Materials and methods
Patients
Thirty-two tumour samples from primary ductal adenocar-
cinoma of the breast, 12 samples from lymph node metas-
tases and 8 from non-involved lymph nodes were obtained
immediately after surgical resection at the Western Infirmary,
Glasgow. Tissue samples were sliced and the tumour and
lymph node cells were spilled by extensive chopping with a
scalpel blade and washed in RPMI 1640 medium (Gibco).
Spilled cells were epithelial in morphology and marker stain-
ing with monoclonal antibodies to HMFG 2 and epithelial
membrane antigens. All samples were analysed for lectin
binding on the day the tissues were collected, as freezing and
thawing resulted in considerable cell death.
The spillage technique was preferred to collagenase treat-
ment as it provided a clean suspension of single cells with
very little cell aggregate and debris and, as such, more
suitable for flow cytometry. However, to ascertain that these
spilled cells did not represent an atypical subpopulation of
tumour cells, one tumour was treated with collagenase
(I5 mg, Worthington Biochemical Corp.) at 37°C overnight
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as well as being spilled. Cell suspensions from both these
samples showed similar staining for both HPA and Con A.
A sample from reduction mammoplasty served as the
source of normal breast tissue. Cells from this tissue sample
were cultured by the method of Wolman et al. (1985) before
staining with the lectins. The tissue mass was treated with
collagenase (15 mg, Worthington Biochemical Corp.) at 37°C
overnight and then washed with RPMI 1640 medium and
seeded in two 25 cm tissue culture flasks containing RPMI
1640 medium and 10% fetal calf serum. Three weeks later
considerable growth of breast epithelial tissue was observed
in one of the flasks. Cells were removed with brief trypsin
treatment and assessed for Class 1 MHC antigens to ensure
that cell surface proteins had not been damaged by this. A
single cell suspension from this culture was prepared by
passing the cells through a 21G needle (Becton Dickinson).
Cells were washed and stained as described for the tumour
and node cells.
Flow cytometry
All flow cytometric studies of lectin binding were carried out
on a FACScan (Becton Dickinson), using the Facscan
Research software for analysis. Fluorescein isothiocyanate
(FITC)- conjugated Helix pomatia (HPA) lectin and
biotinylated succinyl concanavalin A (Con A) lectin, pur-
chased from Sigma Chemical Co., were used at a concentra-
tion of 1 yg ml-'. Spilled cells from tumour and lymph node
were washed twice in phosphate-buffered saline (PBS) and
then resuspended in 50pl of PBS. The cell suspension was
incubated with 100 p1 of the lectin solution on ice for 30
minutes in the dark and then washed twice in PBS. Cell
suspensions treated with biotinylated Con A were further
labelled with streptavidin-phycoerythrin (PE) (Becton Dickin-
son) by adding 10,l of streptavidin-PE solution per test and
incubating for 20 minutes. All cell suspensions were washed
in PBS and finally resuspended in 500 p1 PBS; 10p1l of pro-
pidium iodide (1 ig ml-') were added before acquisition to
provide live/dead discrimination. Controls were included with
each batch of tissue processed to give autofluorescence of
tumour and node cells. 10,000 events per test were acquired
with a gate on fluorescence channel 3 (propidium iodide), to
acquire only the live cells in the suspension, and a live scatter
gate on side scatter (SSC) vs forward scatter (FSC) was used
to gate out the lymphocyte population (Figures la and lb).
The SSC vs FSC gate was essential with cell suspension from
lymph node as it invariably contained a high percentage of
lymphocytes. Near absence (<5%) of lymphocytes in the
acquired lymph node suspension was confirmed using a
'leucogate' antibody (Becton Dickinson).
Sugar inhibition was used to assess the specificity of lectin
binding. A separate tube was treated identically except for
the addition of the appropriate sugar (0.1 M).
Statistical analysis of the data was by the Wilcoxon Signed
Rank Test and the x2 test. Tumour grade was assessed by the
Bloom and Richardson classification (Bloom & Richardson,
1957).
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Figure 1 a, Dual parameter correlated dot plot display of for-
ward (cell size) and side scatter (cell granularity) of lymph node
lymphocytes b, Dual parameter scatter plot (forward scatter ver-
sus side scatter) of cell suspension from a lymph node, showing
the gate drawn to exclude lymphocytes. c, Markers set to define
regions of unbound cells, low intensity and high intensity binding
of the tumour cells to the lectins
Results
Intensity offluorescence andpercentage ofcells with that level
offluorescence
In general, the binding of both HPA and Con A to malig-
nant and normal breast epithelial cells could be categorised
into two groups, a low binding and a high binding cell
population (Figure ic). Cell populations showing
fluorescence intensity ten times brighter than the
autofluorescence were taken to be the low binding group and
the high binding group showed a fluorescence intensity which
was 100 times brighter. It was the percentage of cells in the
high binding group that varied with each specimen analysed
and the extent of which could be correlated with
clinicopathological factors.
The proportion of HPA binding cells (high binding) in the
normal breast epithelial tissue was markedly lower (18%) in
comparison to high Con A binding cells (39%) and these
values were considered to assign cut-off points when relating
lectin binding to clinicopathological features. A tumour hav-
ing >20% of high HPA binding cells was taken to be
positive for, of the various cut-off points assessed, >20%
offered the most informative cut-off value, especially when
related to grade and node involvement. When relating high
Con A binding to various histopathological features the cut-
off >40% was used to assign the relative number ofpositive
Con A binding cells in each specimen analysed. As evident
from Table I, Con A binding showed no correlation with
either grade or node involvement, whereas HPA binding
could be related to nodal involvement (P = 0.001).
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TableI Clinicopathological featuresofbreastcancerpatientsandtheir
relation to HPA and Con A binding
Feature Total Positive HPA Positive Con A
All patients
Age (years)
premenopausal (<49) 5
postmenopausal (>49) 18
Node involvement
-ve 13
+ve 13
Histological grade
0
II
III
Tubule formation
slight/none (1)
moderate (2)
extensive (3)
Nuclear pleomorphism
slight (1)
moderate (2)
severe (3)
Mitotic rate
1
2
3
32 17 (53%) 14 (44%)
3 (60%)
7 (39%)
4 (80%)
10 (56%)
(50%) 2 (15%) 4 (31%)
(50%) 11 (85%) 7 (54%)
4 (14%)
11 (39%)
13 (46%)
2 (7%)
13 (46%)
13 (46%)
1 (4%)
15 (54%)
12 (43%)
5 (18%)
16 (57%)
7 (25%)
0
0 (0%)
6 (55%)
8 (62%)
0 (0%)
6 (46%)
5 (38%)
0 (0%)
10 (67%)
5 (42%)
3 (60%)
7 (44%)
4 (57%)
0
1 (25%)
5 (45%)
6 (46%)
1 (50%)
5 (38%)
4 (31%)
0 (0%)
7 (47%)
5 (42%)
2 (40%)
7 (44%)
4 (57%)
Allofthelistedhistopathological featuresforallthe tumourspecimen
were not available. Grade 0 represents normal breast epithelial cells as
cultured from a reductionmammoplastysample(described in Materials
& Methods).
Correlation ofHPA binding with clinicopathologicalfeatures
Correlation of positive HPA binding with several
clinicopathological factors is shown in Table I. Only node
involvement could be significantly related to HPA binding
(P = 0.001). Though only 5 out of 23 patients of known age
were of the premenopausal group, the percentage of positive
HPA binding (60%) was considerably higher in this group in
comparison to the postmenopausal group (39%). The
difference is, however, statistically not significant (X2 test).
As shown in Table I, a significant positive correlation is
observed between HPA binding and lymph node involvement
(P = 0.001). Only 2 (15%) of a total of 13 node negative
tumours were positive for HPA binding cells, whereas 85%
(11 of 13) of the tumours with involved nodes were positive
for HPA binding. Both the positive HPA patients in the node
negative group had grade II tumours and one of them was in
the premenopausal age group. The two negative HPA
patients in the node positive group had grade I tumour and
were both in the premenopausal age group.
The relationship between HPA binding and tumour grade
is shown in Table I. None of the four grade I tumours was
positive for high HPA binding. However, there was a marked
increase in the number ofpositive HPA tumours in the grade
II and III tumours, with grade III tumours showing a higher
incidence (62%) of HPA binding when compared with the
grade II tumours (55%). Tumours with slight tubule forma-
tion and nuclear pleomorphism had no high HPA binding
cells (Table I) whereas, the moderate and extensive groups
had a higher incidence with the extensive group showing a
lower incidence compared to the moderate group. No cor-
relation is observed with the mitotic rate. There were,
therefore, marked differences between HPA binding to grade
I tumours and tumours of higher grade (II and III), but as
only four grade I tumours were available, these differences
are not statistically significant.
Since HPA binding related significantly to lymph node
involvement (P= 0.001), it was further examined to see how
lymph node involvement and tumour grade related to HPA
binding when considered together (Table II). With grade II
and III tumours, node involvement related with HPA bin-
ding irrespective of grade, since all the grade II and III
tumours with involved nodes were positive for HPA binding,
Table II Positive HPA binding related to tumour grade and node
involvement
Node involvement Grade I Grade II Grade III
+ve 0/2 3/3 8/8
-ve 0/2 2/7 0/4
Values represent number ofpositive HPA tumours/total
whereas only 2 of the grade II and none of the grade III
node-negative tumours were positive for HPA binding. This
relationship, however, does not hold with grade I tumours.
None of the grade I tumours, whether involved or not, were
positive for HPA binding, suggesting that HPA binding cor-
relates with lymph node involvement only with tumours of
higher grade (II and III).
Relationship between HPA binding and Con A binding in
primary tumours
Figure 2 illustrates examples of a dual label analysis of HPA
and Con A binding to breast tumour. This was attempted to
see if positive HPA binding cells were also positive for Con
A binding. Figure 2f is the profile of the normal breast tissue,
having a small proportion of the cells (18%), which were
positive for HPA binding, doubly labelled (quadrant 2,
Figure 2f), while the rest of the cells are bound exclusively to
Con A (quadrant 1, Figure 2f). Though each tumour dis-
played a characterisitc profile of HPA/Con A binding cell
distribution, roughly four distinct features appeared when all
the analysed samples were considered. It is interesting to note
that three tumour samples showed binding patterns consis-
tent with Figure 2b, where the tumours had >70% cells
which bound exclusively to HPA (quadrant 4, Figure 2b) and
all of these samples were from grade III tumours with
involved node. If the two node-negative tumours which were
positive for HPA binding are excluded, Figure 2e appears to
be representative of node-negative tumours, which included
all the four grade I tumours as well as some grade II and III
tumours. Another group with a higher intensity of Con A
binding (not shown) could also be included in the 2e group.
Figure 2c and 2d includes node-positive tumours of grade II
and III and two of the node-negative tumours which were
high on HPA binding. There was, therefore, no consistent
positive or negative correlation between HPA binding and
Con A binding.
Analysis ofspilled tumour cellsfrom the lymph node
In an attempt to see if high binding HPA or Con A cells
could also be detected in the lymph node, spilled cells from
all available lymph nodes were analysed for lectin binding.
For subsequent correlation with histopathology, only nodes
which were involved and for which tumour samples were also
available were chosen. It is of interest to note that all non-
involved node samples were negative for HPA binding (data
not shown) and no relationship was observed with Con A
binding.
There were 12 involved lymph node samples with varying
percentages of involved nodes available for analysis and for
each of these node samples autologous primary tumour sam-
ples were also analysed. To assess the relationship between
HPA binding tumour cells in involved lymph nodes and the
number of nodes involved, all the cases with involved nodes
were grouped into having either less than, or greater than,
50% of examined nodes involved. As shown in Table III, all
the samples (5/5) with >50% of examined nodes involved
were positive for HPA binding in spilled cells from the lymph
nodes. Whereas samples with <50% of involved nodes
showed a lower incidence (4/7) of positive HPA binding.
There was also a significant correlation between positive
HPA tumours and HPA binding cells in the lymph nodes
(P= 0.002), for of the ten tumours positive for HPA binding
all but one of the corresponding lymph node samples were
also positive.
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Figure 2 Dual-label analysis of HPA and Con A binding to breast tumour cells. a, is a control sample. b, is representative of
grade III, node-positive tumours. 3 samples showed binding patterns consistent with this profile. >70% cells showed exclusive
HPA binding in all these samples. c, and d, represents patterns observed with most of the higher grade (II and III) tumours with
involved nodes. e, represents tumours with non-involved nodes. These includes all the 4 grade I tumours and some grade II and
grade III tumours. f, is the profile for the normal breast epithelial tissue as cultured from a reduction mammoplasty sample
Tablelll HPAbindinginspilled tumourcells(non-lymphocytes) from
involved lymph nodes and autologous primary tumours
Positive HPA
% examined nodes
involved Lymph node Tumour
<50 4/7 5/7
> 50 5/5 5/5
Discussion
This study reports the use of flow cytometry as an effective
technique for detecting differences in lectin binding in spilled
cells from fresh breast cancer tissues. In all previous studies
involving lectins, histochemical analysis was performed on
paraffin sections of formalin-fixed tissues and the extent of
lectin binding was determined by a simple visual assessment.
Histochemical analysis suffers from a number of limitations
and, as observed by Dansey et al. (1988), the differences in
binding patterns of PNA and WGA to normal and neoplas-
tic breast tissues was apparent only in an overall impression
when multiple areas of tissues were scanned and the
differences were difficult to quantitate. In this respect, flow
cytometry offers an advantage, since the extent of lectin
binding can be expressed in a defined quantitative fashion
and the percentage of positive cells can readily be deter-
mined.
The data in this study show a significant correlation
between HPA binding and lymph node involvement
(P = 0.001) in tumours of higher grade (Grade II and III).
Grade I tumours were found to be negative for HPA bin-
ding, irrespective of their nodal status. Though there was a
marked difference between HPA binding to grade I tumours
and tumours of higher grade (II and III), the relationship
was statistically not significant. No correlation with any of
the histopathological features was observed with Con A bin-
ding. Although Dansey et al. (1988) have reported no Con A
binding to normal breast epithelial tissue, significant positive
binding (39%) was observed in this study. It must, however,
be added that normal breast tissue in this study was cultured
from a reduction mammoplasty sample.
Spilled tumour cells (non-lymphocytes) from involved
lymph node also show abnormal HPA binding and a rela-
tionship was observed between positive HPA tumours and
HPA binding cells in the lymph node (P = 0.002). Although
present in a higher proportion, lymphocytes can hardly com-
plicate calculation of percent positive HPA cells, since at the
concentration of lectin used (1 Lg ml-') the lymphocyte
population showed no binding to HPA. However, cells from
lymph node samples were acquired with a gate to exclude
lymphocytes (Figure lb).
HPA has binding specificity for terminal N-acetyl galac-
tosamine (GalNac) residues and an elevated level of GalNac
expression in breast cancer suggests that the abnormality
probably lies in the glycosylation pathways. Alteration in
protein glycosylation has previously been linked to malig-
nancy (Ng, et al., 1987; Smets & van Beek, 1984; Turner,
1982). Therapeutic applications can, therefore, be targeted
towards glycosylating enzymes. Identification of defects in
the precise step or steps in the glycosylation pathways would
contribute to such applications. In this study, the binding of
Con A and HPA were directly compared in a simultaneous
two-colour flow cytometric study. HPA has specificity for
terminal GalNAc groups and therefore has the potential to
bind to the N- and 0-linked glycans of glycoproteins. Con A
has specificity for terminal mannose or* glucose groups and
might therefore be reasonably regarded as a specific marker
of the N-linked oligosaccharide groups of glycoproteins.
The fact that HPA binding positivity in the lymph node is
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related to node involvement which, in turn, is related to HPA
binding in tumours, provides a potential for the clinical
exploitation of HPA binding as a metastatic phenotype.
Leathem & Brooks (1987) found HPA binding especially
valuable in predicting prognosis independently of tumour
grade and lymph node status, in addition to its application
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